New and experimental hepatitis C treatment: latest news

New and experimental hepatitis C treatment resources

New and experimental hepatitis C treatment features

New and experimental hepatitis C treatment news from aidsmap

More news

New and experimental hepatitis C treatment news selected from other sources

  • FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3

    The FDA has approved BMS's Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.

    27 July 2015 | AIDSMeds
  • FDA approves Technivie for treatment of chronic hepatitis C genotype 4

    The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).

    27 July 2015 | FDA
  • TAG Pipeline Report

    2015 report on the pipeline for new HIV, HCV and TB drugs.

    17 July 2015 | TAG
  • Gilead pills priced at $1,000 a day are found cost-effective

    Health insurers that have been reluctant to cover hepatitis C drugs with list prices of $1,000 a daily dose will face more pressure after a report concluding the medications are “cost-effective” given their benefits.

    14 July 2015 | Bloomberg
  • Leading Canadian researcher calls for inclusion of co-infected people in large HCV clinical trials

    Stephen Shafran from the University of Alberta performed a major review of clinical trials of many DAA-containing HCV therapies used for the treatment of HCV mono-infection as well as HIV-HCV co-infection. Cure rates of HCV are “remarkably similar” in HCV mono-infected and co-infected participants who were treated with the same regimen and who have the same strain (genotype) of HCV.

    07 July 2015 | CATIE
  • The Medicines Patent Pool Releases Independent Feasibility Studies on Hepatitis C and Tuberculosis

    As part of its ongoing consultation processes on the possibility of the Medicines Patent Pool (MPP) expanding into other disease areas, the organisation has published independent feasibility studies exploring the case for potential entry into Hepatitis C and Tuberculosis.

    07 July 2015 | Medicines Patent Pool
  • FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data

    Specifically, the groups hope to learn about different responses that different patients experienced during clinical trials. Tracy Swan of Treatment Action Group points to relapses in a Harvoni clinical trial that occurred only among African-Americans. The groups also want to perform an independent analysis of poor prognostic factors among people who were not cured in order to identify a patient profile.

    29 June 2015 | Wall Street Journal (blog)
  • AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

    AbbVie, a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis. These new results from AbbVie's Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.

    24 June 2015 | AbbVie press release
  • Achillion partners with J&J to develop hepatitis C drugs

    Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

    20 May 2015 | Reuters
  • ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

    The Phase III programme will evaluate the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-,NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed. In the clinical trials, dolutegravir and rilpivirine will be provided as individual tablets; development of the single-tablet formulation will be concurrent with conduct of the trials.

    06 May 2015 | Viiv Healthcare press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.